Abstract:CNS Neuroscience & TherapeuticsVolume 18, Issue 2 p. 93-101 CLINICAL GUIDELINESOpen Access Chinese Guidelines for the Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack 2010 Yong-Jun Wang, Yong-Jun Wang Neurology Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorSu-Ming Zhang, Su-Ming Zhang Neurology Department, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, ChinaSearch for more papers by this authorLiqun Zhang, Liqun Zhang Neurology Department, St George's Hospital, London, UKSearch for more papers by this authorChun-Xue Wang, Chun-Xue Wang Neurology Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this author Yong-Jun Wang, Yong-Jun Wang Neurology Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorSu-Ming Zhang, Su-Ming Zhang Neurology Department, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, ChinaSearch for more papers by this authorLiqun Zhang, Liqun Zhang Neurology Department, St George's Hospital, London, UKSearch for more papers by this authorChun-Xue Wang, Chun-Xue Wang Neurology Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this author First published: 08 February 2012 https://doi.org/10.1111/j.1755-5949.2011.00290.xCitations: 63 Yong-Jun Wang, Neurology Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Tel.: 0086-010-67098351; Fax: 0086-010-67038316; E-mail: yongjunwang111@yahoo.com.cn and Su-Ming Zhang, Neurology Department, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China. Tel.: 0086-027-83612633; Fax: 0086-027-83612633; E-mail: suming_zhang@163.com and Liqun Zhang, Neurology Department, St George's Hospital, London, UK. Tel.: 44-7837827866; Fax: 44-2087254505; E-mail: lqnzhang@yahoo.com Received 19 October 2011; revision 22 November 2011; accepted 26 November 2011 Writing group: Qiang Dong, Shan Gao, Ru-Xun Huang, Yi-Ning Huang, Chuan-Zhen Lv, Ming Liu, Hai-Qiang Qin, Ming-Li Rao, Yi Xiao, Yu-Ming Xu, Zhong-Hua Yang, Yong-Jun Wang*, Chun-Xue Wang, Ji-Zuo Wang, Wen-Zhi Wang, Jie Wang, Wen-Juan Wang, Jiang Wu, Sheng-Ping Wu, Jin-Sheng Zeng, Su-Ming Zhang*, Liqun Zhang*, Xing-Quan Zhao, Li-Yong Zhong (above sort by family name); on behalf of the guidelines writing group of secondary prevention for ischemic stroke of cerebrovascular disease group of neurologic branch of Chinese medical association. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Introduction Cerebrovascular disease has become the leading cause of mortality and morbidity in China, in both urban and suburb population, with 1,500,000–2,000,000 new strokes each year. After correction for age, the prevalence of stroke is 116–219/100,000/year, and mortality is 58–142/100,000/year. The prevalence of ischemic stroke has increased as the population has aged, and the lifestyle has changed. There are over 7,000,000 stroke survivors living in China, and 70% of them have suffered ischemic stroke. Many of the survivors of ischemic stroke have multiple stroke risk factors, and are at increased risk of recurrent stroke. Many countries have stroke treatment recommendations that are based on data collected in the last decade from random controlled trials (RCTs) on stroke secondary prevention. Although the recommendations provide valuable information, there are considerable differences between Chinese and Western population in regard to genetic background of the population, health conditions, medicine tradition, cultural background, laws/regulations, and welfare systems. It is therefore necessary and urgent to establish stroke treatment guidelines that are relevant to the Chinese population. A panel of experts convened in July 2008 to develop guidelines for ischemic stroke secondary prevention that were specific for the Chinese population. It consisted of experts from neurology, cardiology, endocrinology, intensive care, respiratory, intervention, and epidemiology. The panel conducted a comprehensive review and synthesis of relevant domestic and international literature published before October 2008. When there was sufficient and reliable evidence, the evidence was used; alternatively, current best evidence and experts’ opinions were applied. After wide discussion, multiple editions, and additions of the current evidence, these guidelines have been established. The crucial steps of secondary stroke prevention are to diagnose the causes and recognize the risk factors of stroke beginning with the acute phase of stroke. The risks of recurrent stroke are different, because the causes and the pathophysiological mechanisms of ischemic stroke/transient ischemic attack (TIA), the locations of vascular diseases, risk factors, and patients’ compliance are so variable. It is therefore important to stratify patients into high or low-risk groups based on the causes, and the numbers and severity of risk factors by using tools such as Essen stroke risk scale or the ABCD2 score. Only after stratifying correctly, is it possible to deliver individualized effective treatment and suitable prevention. These guidelines are aimed to provide evidence-based recommendations on the secondary preventions of ischemic stroke/TIA to physicians in neurology, medicine, and other relevant departments in China. Unless specifically mentioned, the recommendations apply to both ischemic stroke and TIA. Please refer to the reference for methods used to classify the classes of evidence and the levels of certainty of the treatment effect [1]. Risk Factor Control Risk factors of stroke can be classified as modifiable and nonmodifiable ones. The goal is to control modifiable risk factors. Please refer to information on primary prevention regarding modifying lifestyle (such as smoking, alcohol excess, obesity, and limited physical activity) to reduce the risk of stroke. This guideline is to focus on the medical management of stroke secondary prevention. Hypertension Hypertension is a major risk factor for stroke/TIA. The prevalence of hypertension has been rising with the rapid socioeconomic growth and lifestyle changes in China. Studies in China suggest a logistic relationship between elevated blood pressure (BP) and the risk of stroke [2]: for every 10 mmHg elevation of systolic BP from baseline, the relative risk of stroke increases 49%; for every 5 mmHg elevation of diastolic BP, the relative risk of stroke increases 46%. The impact strength of hypertension on the risk of stroke in Chinese and Japanese populations is 1.5 times that of western population. A Chinese survey in 2002 showed the diagnose rate of hypertension was 30.2%; the treatment rate was 24.7%; and control rate was only 6.1%. During the same period, the rates of diagnosis, treatment, and control of hypertension in the United States were 70%, 59%, and 34%, respectively. Lowering BP may benefit patients with stroke/TIA on secondary prevention. A systemic review of seven published RCT showed that lowering BP was associated with significant reductions of recurrent stroke, and total vascular events, without significant reductions in fatal stroke and vascular mortality [3]. However, the Prevention Regimen for Effectively Avoiding Second Stroke (ProFESS) trial found no difference in recurrent stroke in patients treated with telmisartan versus placebo [4]. Which antihypertensive medicines are more effective in the prevention of recurrent stroke? The Morbidity and Mortality After Stroke—Eprosartan versus Nitrendipine for Secondary Prevention (MOSES) trial suggested that an angiotensin II type I receptor antagonist (Eprosartan) could significantly lower the rate of recurrent cerebrovascular events when compared with a calcium antagonist (Nitrendipine) [5]. However, a review study on BP control in stroke prevention, which analyzed three head-to-head comparison trials consisted of total of 21,094 patients, suggested that calcium antagonist might be superior to angiotensin receptor blocker, diuretics, and β-blockers [6]. Recommendations 1 BP reduction is recommended for the prevention of recurrent stroke and other vascular events in patients with ischemic stroke/TIA. (Class I, Level of Evidence A). With consideration of age, baseline BP, routine medication, and tolerance, the target BP should be ≤140/90 mmHg, ideally 130/80 mmHg. (Class II, Level of Evidence B). 2 The effects of antihypertensive treatment on the prevention of recurrent stroke/TIA were primarily achieved by lowering BP (Class I, Level of Evidence A). Either a monotherapy or a combination of medicines can be used (Class II, Level of Evidence B). The choice should be individualized. Diabetes Blood glucose control is known to have protective effect on microvascular and macrovascular diseases secondary to Type II diabetes. Poor glucose control is associated with recurrence of stroke. Data on diabetic control in stroke prevention are largely based on primarily prevention. The Action Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial showed intensive control of glucose levels reduced glycated hemoglobin to 6.5%, resulting in a significant reduction in vascular events [7]. For patients with diabetes, intensive lowering BP may significantly improve the combine vascular outcome, including stroke. Epidemiological data have suggested when BP is further reduced to 120/80 mmHg there is a continuous reduction in cardiovascular events [8]. The Collaborative Atorvastatin Diabetes Study (CARDS) showed that statins are effective in reducing the risk of first incidence stroke in diabetic patients [9]. In addition, the Heart Protection Study (HPS) which included 5963 adults with diabetes, suggested add-on statins could reduce the rate of first major vascular events [10]. Recommendations 1 The goal of diabetic glycemic control is glycated hemoglobin of 6.5% or less. However hypoglycemia may be harmful, resulting in increased morbidity. (Class I, Level of Evidence A). 2 For patients with diabetes and hypertension, BP should be strictly controlled below 130/80 mmHg. Specific antihypertensive agents, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers are beneficial in the reduction of vascular events (Class I, Level of Evidence A). In combination with tight glycemic and BP control, statins may decrease the risk of stroke (Class I, Level of Evidence A). Lipid Evidence showed a modest association between elevated total cholesterol levels and an increased risk of ischemic stroke. Lifestyle modifying and statins are the primary lipid-lowering methods. A meta-analysis study which included statins, clofibrate, cholestyramine resin, gemfibrozil, niacin, and diet, showed that all lipid-lowering therapies significantly reduced the incidence of stroke [11]. However, the best efficacy was with statins, especially in secondary prevention, due to their higher potency. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial found that statin treatment may significantly reduce the recurrent rate of stroke/TIA [12]. Although the incidence of hemorrhagic stroke was higher in the statin group, there was no difference in outcome. A meta-analysis involving 121,000 patients demonstrated that prolonged statin treatment provided significant primary protection in patients at high risk of vascular diseases, without significantly elevated risk of hemorrhagic stroke [13]. For elderly patients with normal liver and renal function, the doses of lipid-lowering agents do not need to be adjusted. However, the treatment should be individualized, with lower doses initially and close monitoring [14]. Recommendations 1 Patients with ischemic stroke/TIA and elevated cholesterol should be managed with a combination of treatments including lifestyle and dietary modifications, and medications. Statins are recommended lipid-lowering agents. It is reasonable to target the low-density lipoprotein Cholesterol (LDL-C) ≤ 2.59 mmol/L or a 30–40% reduction in LDL-C (Class I, Level of Evidence A). 2 For patients with stroke/TIA and multiple risk factors (such as coronary artery disease, diabetes, current smoking, metabolic syndrome, cerebrovascular atherosclerosis without evidence of unstable plaque, arterial thrombosis or peripheral arterial disease), it is reasonable to target a LDL-C level of <2.07 mmol/L or a reduction of >40% in LDL-C (Class I, Level of Evidence A). 3 Patients with ischemic stroke/TIA and evidence of intra- and extracranial large artery atherosclerosis and unstable plaques or arterial thrombosis, are recommended early intensive statin therapy to target a LDL-C level of <2.07 mmol/L or a reduction of >40% in LDL-C (Class III, Level of Evidence C). 4 In general, long-term use of statins is safe. Before and during statin therapy, monitoring symptoms such as muscle pain, and liver enzymes (e.g., Alanine transaminase and aspartate transaminase) and muscle enzyme (creatine kinase) is required. If those markers are persistently elevated without other identifiable causes, statins should be reduced or discontinued (Discontinuation of statins was recommended when transaminases are more than three times the normal upper limits, or creatine kinease is more than five times the normal upper limit.) (Class I, Level of Evidence A). For elderly patients with multiple organ insufficiency, or taking multiple medications, drug–drug interactions and potential side effects should be closely monitored (Class III, Level of Evidence C). 5 If patients have a history or at high risk of intracranial hemorrhage, caution should be exercised with statin therapy (Class II, Level of Evidence B). Interventional Approaches for the Patient with Large-Artery Atherosclerosis Carotid Endarterectomy The North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST) showed carotid endarterectomy (CEA) reduced the risk of ipsilateral stroke in patients with symptomatic high-grade stenosis (70–99%) of the internal carotid artery [15, 16]. CEA is also beneficial to patients with symptomatic moderate (50–69%) ipsilateral carotid stenosis [17]. However, for patients with mild to moderate carotid stenosis (<50%), the possible benefits of CEA were outweighed by the risks of surgery. Early CEA may be associated with increased benefits, ideally within 2 weeks of their last ischemic event. Elderly patients (>75 years of age) without organ failure or severe cardiac dysfunction can also benefit from CEA. Women with severe symptomatic carotid stenosis (>70%) should consider CEA; however, women with less severe stenosis can be treated medically. It is important to prevent perioperative stroke during the procedure. The American Heart Association (AHA)/American Stroke Association Council on Stroke recommend that CEA can only be performed by a surgeon with a perioperative complication rate (combined morbidity and mortality) <6%[18]. Patients with carotid stenosis should take low-dose aspirin before and after surgery [19]. Recommendations 1 For patients with recent ischemic stroke/TIA and severe (70–99%) ipsilateral carotid artery stenosis, CEA is recommended (Class I, Level of Evidence A). 2 For patients with recent ischemic stroke/TIA and moderate (50–69%) ipsilateral carotid stenosis, CEA is recommended depending on patient-specific factors, such as age, sex, comorbidities and the severity of stroke (Class I, Level of Evidence A). CEA may benefit the most to men ≥75 years of age with their last hemispheric ischemic events within 2 weeks (Class III, Level of Evidence C). 3 CEA is recommended within 2 weeks of last ischemic event when indicated (Class II, Level of Evidence B). 4 CEA is not recommended for patients with carotid stenosis <50% (Class I, Level of Evidence A). 5 Continuation of antiplatelet therapy is recommended postoperatively (Class I, Level of Evidence A). Endovascular Intervention for Extra and Intracranial Stenosis Many reports suggested that Angioplasty and Stenting (CAS) can improve the outcome in patients with symptomatic carotid stenosis, but there is no evidence that CAS is superior to CEA. There is no clinical trial directly comparing the effectiveness of CAS with the best medical management. The Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS) showed CAS has comparable effectiveness as CEA on stroke secondary prevention in patients with symptomatic carotid stenosis, with less cranial neuropathy and major neck hematoma, but higher rates of restenosis [20]. A meta-analysis showed that CAS was associated with a greater 30-day risk of stroke/death when compared with CEA [21]. Intracranial angioplasty and/or stenting have been approved as safe procedures with a high degree of technical success when performed by experienced surgeons. However, the high rate of recurrent stenosis is unsolved [22]. Recommendations 1 For patients with symptomatic severe carotid stenosis (>70%), when CEA is not available, CAS may be considered, (Class IV, Level of Evidence D). For patients with symptomatic severe carotid stenosis (>70%) that are difficult to access surgically, early recurrent stenosis after CEA, and radiation-induced stenosis, CAS may be considered (Class II, Level of Evidence B). CAS may be considered in elderly patients with caution (Class II, Level of Evidence B). 2 For patients with symptomatic intracranial carotid stenosis, endovascular intervention may be effective (Class II, Level of Evidence B). 3 Combination of aspirin and clopidogrel should be given before stenting, and continued for at least 1 month after surgery. Clopidogrel alone is also recommended thereafter for at least 12 months (Class IV, Level of Evidence D). Medical Treatment for Patients with Cardiogenic Embolism Atrial Fibrillation A Cochrane review in 1995 showed that warfarin reduced the odds of recurrent stroke by two-thirds, with no reported intracranial hemorrhage [23]. In 2002, collaborative meta-analysis from Antithrombotic Trialists’ Collaboration suggested that antiplatelet agents reduced the risk of nonfatal stroke by about a quarter [24]. In 2005, the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W) demonstrated warfarin is superior to clopidogrel plus aspirin in prevention of vascular events in patients with atrial fibrillation, with comparable risk of major bleeding [25]. Later (2009) ACTIVE A showed that in patients with atrial fibrillation who were unsuitable to warfarin, the addition of clopidogrel to aspirin significantly reduced the risk of major vascular events compared with aspirin alone [26]. However, the risks of major hemorrhage, including intracranial bleeding were increased in the dual antiplatelet group, although not significant in fatal hemorrhage. In 2006, an RCT, comparing warfarin and aspirin in the prevention of embolic stroke in Chinese patients with atrial fibrillation without valvular diseases, showed warfarin had significantly better primary outcomes when compared with aspirin, although not significant in mortality [27]. Warfarin is effective, but it has a narrow treatment range, requiring frequent monitoring international normalized ratio (INR) and adjusting doses. Internationally, when warfarin is used for stroke prevention in patients with atrial fibrillation, the effective and safe target INR range of 2.0–3.0 is recommended. A study on the safety and the effectiveness of warfarin in Chinese patients with atrial fibrillation suggested that a target INR range of 1.5–3.0 [28]. However, this result requires further verification. Recommendations 1 For patients with ischemic stroke/TIA and atrial fibrillation (including paroxysmal atrial fibrillation), oral anticoagulation with warfarin (target INR range of 2.0–3.0) is recommended to prevent secondary stroke (Class I, Level of Evidence A). 2 For patients unable to take oral anticoagulants, antiplatelet agents were recommended (Class I, Level of Evidence A). In addition, combination of clopidogrel and aspirin may be superior to aspirin alone (Class I, Level of Evidence A). Acute Myocardial Infarction (MI) and Left Ventricular (LV) Thrombus Patients with acute MI and complicated with stroke are at very high risk of recurrent vascular events. The major risk factors for stroke in the setting of acute MI are anterior MI, hypertension, atrial fibrillation, previous stroke, and advanced age. The American College of Cardiology (ACC)/AHA guidelines for the management of patients with ST-elevation myocardial infarction (STEMI) recommended daily long-term aspirin (clopidogrel, if aspirin is contraindicated) as secondary prevention [29]. In clinically indicated patients (e.g., atrial fibrillation and LV thrombus), warfarin is recommended with a target INR range of 2.0–3.0. For patients with LV thrombus following MI and complicated with ischemic stroke/TIA, warfarin is recommended for 3 months to 1 year. Recommendations 1 Patients with ischemic stroke/TIA in the setting of acute MI, aspirin 75– 325 mg daily is recommended (Class I, Level of Evidence A). 2 Patients with ischemic stroke/TIA in the setting of acute MI complicated with LV mural thrombus, should be treated with warfarin for at least 3 months (up to 1 year) with target INR of 2.0–3.0 (Class II, Level of Evidence B). Valvular Heart Disease 1 Rheumatic Mitral Valve disease: Patients with rheumatic mitral valve disease and previous embolic event, have a high risk of recurrent embolism. Long-term anticoagulant therapy may effectively reduce embolic events in those patients. It has been demonstrated by transesophageal echocardiogram that long-term anticoagulant therapy may result in disappearance of left atrial thrombus [30]. ACC/AHA guidelines for the management of patients with valvular heart disease recommended anticoagulant therapy in patients with mitral stenosis and one of the following conditions: atrial fibrillation (paroxysmal, persistent or permanent), a history of embolic event (even in sinus rhythm), or left atrial thrombus [31]. 2 Nonrheumatic Mitral Valve diseases: There are two nonrheumatic mitral valve diseases associated with stroke: mitral valve prolapse and mitral annular calcification. To date there have been no clinical trials addressed the efficacy of antithrombotic therapies for patients with mitral valve prolapse. Some observational studies suggested antiplatelet therapy for patients with mitral valve prolapse and a prior thrombus event; and anticoagulation or antiplatelet for patients with mitral annular calcification and prior thrombus events. ACC/AHA guidelines for the management of patients with valvular heart disease recommended aspirin (75–325 mg daily) for patients with mitral valve prolapse and prior cerebral TIA [31]. Warfarin is also recommended for stroke patients with mitral valve prolapse, and complicated with mitral regurgitation, atrial fibrillation, or left atrial thrombus. 3 Aortic Valve Disease: Although autopsy studies have reported systemic embolism in about one-third of cases with calcific aortic valves, there have been no randomized clinical trials on patients with stroke/TIA and aortic valve disease [32]. 4 Cardiac Valve repair and prosthetic heart valves: There have been no random clinical trials to specifically address secondary stroke prevention in patients with cardiac valve repair or prosthetic heart valves. The European Society of Cardiology (ESC) published guidelines on the anticoagulation management of patients with valvular heart disease which suggested targeting INR should take into account patients’ risk factors and the thrombogenicity of the prosthesis [33]. Recommendations 1 For patients with ischemic stroke/TIA and rheumatic mitral valve disease, with or without atrial fibrillation, long-term anticoagulation with warfarin with a target INR range of 2.0–3.0 is recommended (Class III, Level of Evidence C). Antiplatelet agents should not be added to warfarin to avoid increasing bleeding risk (Class III, Level of Evidence C). 2 For patients with ischemic stroke/TIA and rheumatic mitral valve disease, who suffered recurrent ischemic stroke/TIA while on adequate anticoagulation, addition of antiplatelet to warfarin is reasonable (Class III, Level of Evidence C). 3 For patients with ischemic stroke/TIA and mitral valve prolapse, antiplatelet therapy may be considered (Class III, Level of Evidence C). 4 For patients with ischemic stroke/TIA and mitral valve insufficiency, atrial fibrillation or left atrial thrombus, long-term warfarin therapy is recommended (Class III, Level of Evidence C). 5 For patients with ischemic stroke/TIA and mitral annular calcification, antiplatelet or warfarin may be considered (Class IV, Level of Evidence D). 6 For patients with ischemic stroke/TIA and aortic valve disease, antiplatelet therapy is recommended (Class III, Level of Evidence C). 7 For patients with ischemic stroke/TIA who have mechanical prosthetic heart valves, anticoagulation with warfarin is recommended with a target INR range of 2.5–3.5 (Class II, Level of Evidence B). 8 For patients with ischemic stroke/TIA who have bioprosthetic heart valves or mechanic prosthetic heart valve with low thrombogenicity, anticoagulation with warfarin with a target INR range of 2.0–3.0 is recommended (Class II, Level of Evidence B). 9 For patients with ischemic stroke/TIA and treated with warfarin, who have recurrent ischemic stroke/TIA with a target INR, addition of antiplatelet may be considered (Class III, Level of Evidence C). Cardiomyopathy and Heart Failure Patients with dilated cardiomyopathy have a high risk of intracardial mural thrombus formation. For patients with atrial fibrillation or are at high risks of thrombus events such as deep vein thrombosis, aspirin 75–100 mg daily may be used to prevent mural thrombus. Patients with ischemic stroke/TIA and identified mural thrombi should be treated with long-term oral anticoagulation with warfarin (target INR of 2.0–3.0). For patients with chronic heart failure, the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial did not show any significant difference between warfarin and aspirin or clopidogrel at primary vascular outcome, including stroke. However, there were more bleeding events in the warfarin group [34]. Recommendations 1 For patients with ischemic stroke/TIA and dilated cardiomyopathy, antiplatelet therapy or warfarin (INR 2.0–3.0) may be considered to prevent recurrent ischemic events (Class III, Level of Evidence C). 2 For patients with ischemic stroke/TIA and chronic heart failure, antiplatelet may be considered (Class III, Level of Evidence C). Antithrombotic Therapy for Noncardioembolic Stroke or TIA Noncarioembolic strokes/TIAs are ischemic events caused by atherosclerotic disease, occlusion of small arteries, or crytogenic infarcts. Antiplatelet Agents Antiplatelet therapy may significantly reduce the risks of vascular death, nonfatal MI, and nonfatal stroke, in patients with previous stroke/TIA [24]. 1 Aspirin: Aspirin (50–1300 mg daily) provide some prevention for recurrent stroke, regardless of the dosage. However, high doses of aspirin have a higher risk of gastrointestinal bleed [18]. 2 Clopidogrel: Compared with aspirin, clopidogrel may be more effective in reducing the combined risk of ischemic stroke, MI, and vascular death [35]. The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabliation, Management, and Avoidance (CHARISMA) trial suggested that clopidogrel may be more beneficial than aspirin in patients with symptomatic atherothrombosis disease [36]; however, it may not be so in patients with multiple risk factors. 3 Dipyridamole: Regardless of its formula, dipyridamole may reduce cerebrovascular events, but not death from vascular events. There is no evidence that dipyridamole is more effective than aspirin. 4 Dipyridamole and aspirin: The second European Stroke Prevention Study (ESPS2) showed that combination therapy of aspirin 25 mg twice a day and extended-release dipyridamole 200 mg twice a day significantly reduced the risk of stroke or death from vascular events when compared with aspirin alone [37]. 5 The PRoFESS trial showed no difference in the recurrence rate of stroke between the clopidogrel group and the dipyridamole and aspirin combination group. However, major bleeding events (including intracranial hemorrhage) were more common in the combination group [38]. Headache is also a more common side effect in the combination group, which decreased compliance in this group. 6 Clopidogrel and aspirin: The management of Atherotherombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attacks or Ischemic Stroke (MATCH) trial showed no significant benefit of clopidogrel 75 mg plus aspirin 75 mg combination therapy when compared with clopidogrel 75 mg alone in reducing major vascular events [39]. The risk of major bleeding was significantly increase

Abstract:HomeStrokeVol. 53, No. 9Treatment and 1-Year Prognosis of Ischemic Stroke in China in 2018: A Hospital-Based Study From Bigdata Observatory Platform for Stroke of China Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplemental MaterialFree AccessResearch ArticlePDF/EPUBTreatment and 1-Year Prognosis of Ischemic Stroke in China in 2018: A Hospital-Based Study From Bigdata Observatory Platform for Stroke of China Wen-Jun Tu, Feng Yan, Bao-Hua Chao, Lei Cao and Longde Wang Wen-Jun TuWen-Jun Tu https://orcid.org/0000-0002-1703-1802 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (W.-J.T.). The General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China (W.-J.T., F.Y., B.-H.C., L.C., L.W.). , Feng YanFeng Yan The General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China (W.-J.T., F.Y., B.-H.C., L.C., L.W.). , Bao-Hua ChaoBao-Hua Chao The General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China (W.-J.T., F.Y., B.-H.C., L.C., L.W.). , Lei CaoLei Cao The General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China (W.-J.T., F.Y., B.-H.C., L.C., L.W.). and Longde WangLongde Wang Correspondence to: Longde Wang, MD, No. 118, Guang'anmen Inner St, Beijing, 100053, China. Email E-mail Address: [email protected] https://orcid.org/0000-0002-2156-7909 The General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China (W.-J.T., F.Y., B.-H.C., L.C., L.W.). Originally published22 Jul 2022https://doi.org/10.1161/STROKEAHA.121.038260Stroke. 2022;53:e415–e417Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: July 22, 2022: Ahead of Print Stroke is associated with the highest disability-adjusted life years lost in China, with over 2 million new cases annually.1 In addition, deaths caused by stroke are rising rapidly in China, more so than in other countries.2 However, there are few studies that have provided nationwide data on stroke treatment and outcomes in China. This study aims to assess the treatment and 1-year prognosis of ischemic stroke in China in 2018.MethodsIn December 2017, we randomly selected 100 hospitals (at least one in each province) from the Bigdata Observatory Platform for Stroke of China3 (Supplemental Material I). Hospitals participating in the Bigdata Observatory Platform for Stroke of China included mandatory and voluntary. From January to December 2018, all patients with first-ever ischemic stroke and symptom onset within 14 days were included. The Ethics Committee of Brain Hospital of Hunan Province (No. Z2017006) and Peking Union Medical College Hospital (JS-2289) approved this study, and written informed consent was obtained. A complete description of the information collected has been reported previously.3 Telephone follow-up was conducted after 1 year after baseline. Case fatality, disability, and recurrence rates were assessed, and a percentage and 95% CIs were presented. Multivariable logistic regression was used to examine the association of variables with the odds of outcomes (Supplemental Material II).ResultsIn total, 74 904 ischemic strokes from 83 hospitals from 30 provinces (median [interquartile range] age, 68 [58–74] years; 61.27% male) were recruited. Two thousand six hundred eighty-nine (3.59% [95% CI, 3.46%–3.72%]) patients received thrombolytic therapy and 820 (1.09%) patients received thrombectomy treatment. At discharge, the fatality rate was 1.23% (95% CI, 1.15%–1.31%). The discharge against medical advice rate was 5.34% (95% CI, 5.18%–5.50%; Table S1). In-hospital fatality rate was higher in those old patients (≥60 years) than in those young patients (<60 years). There were regional differences in the in-hospital fatality rate (Figure).Download figureDownload PowerPointFigure. Subgroup analysis in the discharge and 1-y follow-up (those results were unweighted data as % [95% CI]). Disability was defined as an modified Rankin Scale (mRS) of 3 to 5 points. bModel covariates were age, sex, history of stroke, hypertension, diabetes, hyperlipidemia, atrial fibrillation, coronary artery disease, coagulopathy, heart failure, peripheral arterial disease, carotid stenosis, hyperhomocysteinemia, stroke severity, hospital grade, region, stroke unit, and teaching hospital status. Sex: female vs male; age: ≥60 vs <60. cThe highest-level region vs lowest region; in-hospital fatality: Northwest China (NW) vs CC, in-hospital fatality/discharge against medical advice (DAMA): SW vs NC; 1-year fatality: SC vs North China (NC), 1-year recurrence: Northeast China (NE) vs SC, 1-year disability: SC vs NC. d,e,fRepresent the P for each region compared with North China (NC), which we have selected as the reference region; dFor P<0.05, efor P<0.01, and ffor P<0.001. CC indicates Central China; EC, East China; N, number of patients; n, number of hospitals; and SW, Southwest China.During the follow-up period, the fatality rate was 6.81% (95% CI, 6.62%–7.00%; Table S2. The fatality rate was higher in those old patients than in those young patients. In addition, men patients had a lower fatality rate than women. The fatality rate varied significantly between different regions (Figure). The case recurrence rate was 7.74% (95% CI, 7.54%–7.94%), and the disability rate of stroke survivors was 15.42% (95% CI, 15.14%–15.70%; Table S2). Stroke recurrence rate and disability rate of stroke survivors were higher in those old patients than in those young patients and varied greatly between different regions (Figure).DiscussionThis nationwide study shows the rate of thrombolytic therapy and 1-year outcomes in patients with ischemic stroke. Another study showed that the in-hospital death/discharge against the medical advice rate was 5.3% (5.0%–5.5%) for ischemic stroke.4 The China Kadoorie Biobank showed that among those who survived 28 days after the first stroke, the 1-year case fatality and recurrence rates were 4% and 17%.5 The prognosis of ischemic stroke in China is better than in high-income countries despite the low thrombolytic rates.1 Furthermore, the fatality and disability rates trend are low in north China and high in the south, while the recurrence rate shows the opposite direction. Hospitals with a low sample size and low follow-up rate were excluded. This may cause selection bias as patients in these excluded hospitals might have less access to treatment and worse outcomes. This study provides a scientific basis for the Chinese population by establishing a database of stroke patients in China, studying the rules and trends of disease treatment and prognosis.Article InformationSources of FundingThis study was supported by the National Major Public Health Service Projects.Supplemental MaterialBigdata Observatory Platform for Stroke of ChinaSupplemental Materials and MethodsTables S1–S2FootnotesSupplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.121.038260.Correspondence to: Longde Wang, MD, No. 118, Guang'anmen Inner St, Beijing, 100053, China. Email wangld@nhfpc.gov.cnReferences1. Wu S, Wu B, Liu M, Chen Z, Wang W, Anderson CS, Sandercock P, Wang Y, Huang Y, Cui L, et al; China Stroke Study Collaboration. Stroke in China: advances and challenges in epidemiology, prevention, and management.Lancet Neurol. 2019; 18:394–405. doi: 10.1016/S1474-4422(18)30500-3CrossrefMedlineGoogle Scholar2. Li Z, Jiang Y, Li H, Xian Y, Wang Y. China's response to the rising stroke burden.BMJ. 2019; 364:l879. doi: 10.1136/bmj.l879CrossrefMedlineGoogle Scholar3. Shen Y, Chao BH, Cao L, Tu WJ, Wang LD. Stroke center care and outcome: results from the CSPPC stroke program.Transl Stroke Res. 2020; 11:377–386. doi: 10.1007/s12975-019-00727-6CrossrefGoogle Scholar4. Tu WJ, Chao BH, Ma L, Yan F, Cao L, Qiu H, Ji XM, Wang LD. Case-fatality, disability and recurrence rates after first-ever stroke: a study from bigdata observatory platform for stroke of China.Brain Res Bull. 2021; 175:130–135. doi: 10.1016/j.brainresbull.2021.07.020CrossrefGoogle Scholar5. Chen Y, Wright N, Guo Y, Turnbull I, Kartsonaki C, Yang L, Bian Z, Pei P, Pan D, Zhang Y, et al. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0· 5 million Chinese adults.Lancet Glob Health. 2020; 8:e580–e590. doi: 10.1016/S2214-109X(20)30069-3CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Tu W and Xu Y (2023) A response to a letter to the editor TR-D-22-00887, Thrombosis Research, 10.1016/j.thromres.2023.01.009, 223, (34-35), Online publication date: 1-Mar-2023. Tu W, Xu Y, Chen H, Li J and Du J (2023) Impact of the COVID-19 pandemic lockdown on hospitalizations for cerebrovascular disease and related in-hospital mortality in China: A nationwide observational study, Archives of Gerontology and Geriatrics, 10.1016/j.archger.2022.104832, 104, (104832), Online publication date: 1-Jan-2023. Tu W, Xu Y, Liu Y, Du J and Zhao J (2022) Endovascular thrombectomy or bridging therapy in minor ischemic stroke with large vessel occlusion, Thrombosis Research, 10.1016/j.thromres.2022.09.020, 219, (150-154), Online publication date: 1-Nov-2022. September 2022Vol 53, Issue 9 Advertisement Article InformationMetrics © 2022 American Heart Association, Inc.https://doi.org/10.1161/STROKEAHA.121.038260PMID: 35866427 Originally publishedJuly 22, 2022 Keywordsischemic strokeprognosisdisability-adjusted life yearshospitaltreatment outcomePDF download Advertisement SubjectsIschemic Stroke

Secondary Prevention Of Ischemic Stroke In Urban China

Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up

Implementation Of A Structured Guideline-Based Program For The Secondary Prevention Of Ischemic Stroke In China

Characteristics of High Risk People with Cardiovascular Disease in Chinese Rural Areas: Clinical Indictors, Disease Patterns and Drug Treatment

Disparities in Secondary Prevention between Stroke and Coronary Heart Disease in China: Cross-Sectional Community-Based Study, 2014–2016

Use of Drug Treatment for Secondary Prevention of Cardiovascular Disease in Urban and Rural Communities of China: China Kadoorie Biobank Study of 0.5 Million People

A study on medication in the secondary prevention of ischemic stroke

Chinese Guidelines for the Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack 2010.

Abstract P396: Hospital Management of Major Stroke Types in Urban and Rural China: Findings from a 11-Year Community-Based Studies Involving >20,000 Hospitalized Stroke Cases

Treatment and 1-Year Prognosis of Ischemic Stroke in China in 2018: A Hospital-Based Study from Bigdata Observatory Platform for Stroke of China

Use of Cardiovascular Prevention Treatments after Acute Coronary Syndrome in China and Associated Factors.

Stroke Prevention Knowledge and Prestroke Health Behaviors among Hypertensive Stroke Patients in Mainland China

Status and costs of primary prevention for ischemic stroke in China.

[The prevalence and status of pre-hospital treatments of risk factors among patients with stroke in China].

Temporal trends and rural-urban disparities in cerebrovascular risk factors, in-hospital management and outcomes in ischaemic strokes in China from 2005 to 2015: a nationwide serial cross-sectional survey

Current Management of Intracerebral Haemorrhage in China: a National, Multi-Centre, Hospital Register Study

Change in Stroke Incidence from a Population-Based Intervention Trial in Three Urban Communities in China

Fixed-Dose Combination Treatment after Stroke for Secondary Prevention in China

Secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack

Hospital management of major stroke types in Chinese adults: a population-based study of 20 000 hospitalised stroke cases

Investigation of vascular risk factor control and secondary prevention medication compliance in acute ischemic stroke